Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 2/20 | 0.57 |
| ▸ | NPC1 | O15118 | 4/20 | 0.45 |
| ▸ | RAB9A | P51151 | 4/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | SYK | P43405 | 3/20 | 0.43 |
| ▸ | BTK | Q06187 | 2/20 | 0.43 |
| ▸ | JAK2 | O60674 | 3/20 | 0.43 |
| ▸ | JAK1 | P23458 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.40 |
| ▸ | FLT1 | P17948 | 2/20 | 0.40 |
| ▸ | CFTR | P13569 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.40 |
| ▸ | CLK2 | P49760 | 3/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.40 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4553908 | 0.86 | KDR (0.54) | KDRNPC1RAB9AHPGDSMN1; SMN2 | |
| SCHEMBL3894031 | 0.86 | KDR (0.58) | KDRNPC1RAB9AHPGDSMN1; SMN2 | |
| SCHEMBL3891570 | 0.86 | KDR (0.58) | KDRNPC1RAB9AHPGDSMN1; SMN2 | |
| SCHEMBL4554698 | 0.85 | WNT3A (0.54) | KDRNPC1RAB9AHPGDSMN1; SMN2 | |
| SCHEMBL4554160 | 0.84 | KDR (0.60) | KDRNPC1RAB9AHPGDSMN1; SMN2 | |
| SCHEMBL3889743 | 0.83 | KDR (0.64) | KDRNPC1RAB9AHPGDSMN1; SMN2 | |
| SCHEMBL3890853 | 0.81 | KDR (0.55) | KDRNPC1RAB9AHPGDSMN1; SMN2 | |
| SCHEMBL3891272 | 0.81 | KDR (0.60) | KDRNPC1RAB9AHPGDSMN1; SMN2 | |
| SCHEMBL187444 | 0.81 | KDR (0.72) | KDRNPC1RAB9AHPGDSMN1; SMN2 | |
| SCHEMBL3891696 | 0.80 | KDR (0.66) | KDRNPC1RAB9AHPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4392348-B2 | — | — | 2009-12-24 | — | — | JP | claimed |
| US-7102009-B2 | Substituted amine derivatives and methods of use | AMGEN INC. (US) | 2006-09-05 | — | — | US | claimed |
| JP-2006502118-A | — | — | 2006-01-19 | — | — | JP | claimed |
| EP-1562933-A2 | SUBSTITUTED AMINE DERIVATIVES AND METHODS OF USE IN THE TREATMENT OF ANGIOGENESIS RELATED DISORDERS | Amgen Inc. (US) | 2005-08-17 | — | — | EP | claimed |
| WO-2004007481-A2 | SUBSTITUTED AMINE DERIVATIVES AND METHODS OF USE IN THE TREATMENT OF ANGIOGENESIS RELATES DISORDERS | AMGEN INC. (US) | 2004-01-22 | — | — | WO | claimed |
| US-20030203922-A1 | Substituted amine derivatives and methods of use | AMGEN INC. | 2003-10-30 | — | — | US | claimed |
| US-7102009-B2 | Substituted amine derivatives and methods of use | AMGEN INC. (US) | 2006-09-05 | — | — | US | disclosed |
| EP-1562933-A2 | SUBSTITUTED AMINE DERIVATIVES AND METHODS OF USE IN THE TREATMENT OF ANGIOGENESIS RELATED DISORDERS | Amgen Inc. (US) | 2005-08-17 | — | — | EP | disclosed |
| WO-2004007481-A2 | SUBSTITUTED AMINE DERIVATIVES AND METHODS OF USE IN THE TREATMENT OF ANGIOGENESIS RELATES DISORDERS | AMGEN INC. (US) | 2004-01-22 | — | — | WO | disclosed |
| US-20030203922-A1 | Substituted amine derivatives and methods of use | AMGEN INC. | 2003-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203922-A1 | Substituted amine derivatives and methods of use | MAOB, HNMT, FLT4 | KDR 13/4885NPC1 782/4885RAB9A 2278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.